Show results for
Refine by
Therapeutics To Collaborate On Developing Suppliers In Canada
6 companies found
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Acuitas is a private company based in Vancouver, British Columbia and was founded in February 2009. We are partnered with multiple pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the ...
Proteins are the “workhorses” within cells responsible for metabolic processes, transport processes and structural elements. They are coded by genes on DNA and this code is transcribed into a message (messenger RNA or mRNA) within the ...
based inVictoria, BRITISH COLUMBIA (CANADA)
IPA (ImmunoPrecise Antibodies NASDAQ: IPA ) is a biotherapeutic research company that brings industry leading antibody discovery services and complex artificial intelligence technologies together - to lead its pharmaceutical partners into the era of ...
based inEdmonton, ALBERTA (CANADA)
Akshaya Bio Inc. (Akshaya) is a privately held development stage biotechnology company located in Edmonton, Alberta, Canada. Akshaya develops innovative therapeutics for infectious diseases and cancer. Akshaya's proprietary Chimigen® Platform ...
The Chimigen® Platform is a flexible platform vaccine technology designed to elicit both humoral and cellular immune responses in ...
based inPROVIDENCE, RHODE ISLAND (USA)
At Kiffik, we’ve developed novel technology that allows completely non-invasive access to interstitial fluid that fits in a wearable, connected device capable of transmitting health data from nearly anywhere in the world. Kiffik Biomedical, Inc. ...
based inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon ...